VoxNeuro, a Software as a Medical Device (SaMD) brain health company that analyzes brain-based biomarkers to assess cognitive function, recently announced a research partnership with Boston University and the launch of Clinical Studies Focusing on mild-Traumatic Brain Injury/Concussion and Alzheimer's disease.
VoxNeuro, in partnership with Boston University, has launched two studies that will evaluate its cognitive health assessment platform in an outpatient setting to assess diagnostic accuracy. The studies will focus on patients suffering from mild-Traumatic Brain Injury (mTBI)/Concussion and Alzheimer’s disease, respectively.
VoxNeuro is an OBIO® member.